Amgen: Renal Insufficiency, Chronic trials

The registry lists 50 Renal Insufficiency, Chronic studies with Amgen as lead sponsor. 2 are open to participants now and 27 have results posted.

Phase 1 4Phase 2 3Phase 3 29Phase 4 8No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving HemodialysisRecruitingNCT03969329Phase 3
• A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisRecruitingNCT03633708Phase 3
• Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)CompletedNCT03299244Phase 3Results posted
• A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving HaemodialysisCompletedNCT02833857Phase 1Results posted
• Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on DialysisCompletedNCT02341417Phase 3Results posted
• Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving HemodialysisCompletedNCT02253654Phase 4Results posted
• Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on DialysisTerminatedNCT02138838Phase 3Results posted
• Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on HemodialysisCompletedNCT02102204Phase 3Results posted
• Head-to-Head Study of Etelcalcetide (AMG 416) and CinacalcetCompletedNCT01896232Phase 3Results posted
• Study of South African Dialysis PatientsTerminatedNCT01890577Results posted
• Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on HemodialysisCompletedNCT01788046Phase 3Results posted
• Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on HemodialysisCompletedNCT01785875Phase 3Results posted
• Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on HemodialysisCompletedNCT01785849Phase 3Results posted
• Study to Evaluate the Prospective Payment SystemCompletedNCT01717989Results posted
• Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney DiseaseCompletedNCT01652872Phase 3Results posted
• Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on DialysisCompletedNCT01464931Phase 1Results posted
• Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary HyperparathyroidismTerminatedNCT01439867Phase 2Results posted
• Study to Evaluate Cinacalcet in Children With Chronic Kidney DiseaseCompletedNCT01290029Phase 1Results posted
• Pediatric Chronic Kidney Disease Safety and EfficacyTerminatedNCT01277510Phase 3Results posted
• Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant RecipientsCompletedNCT00975000Phase 3Results posted
• Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney DiseaseCompletedNCT00925587Phase 3Results posted
• European Union Registry in Paediatric Chronic Kidney Disease Patients Looking at Safety and Usage Patterns of Darbepoetin AlfaCompletedNCT00838097Results posted
• 20070360 Incident DialysisCompletedNCT00803712Phase 4Results posted
• LEARN-6™: A Prospective, Observational Nursing Home StudyCompletedNCT00727571Results posted
• Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney DiseaseTerminatedNCT00436748Phase 3Results posted
• ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving HemodialysisCompletedNCT00379899Phase 4Results posted
• STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) PatientsTerminatedNCT00364845Phase 3Results posted
• E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular EventsCompletedNCT00345839Phase 3Results posted
• Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency PatientsCompletedNCT00042432Phase 2Results posted
• Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on DialysisCompletedNCT02185911
• Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney DiseaseWithdrawnNCT01428154Phase 1
• Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With HyperphosphatemiaCompletedNCT00530114Phase 2
• Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving DialysisCompletedNCT00436995Phase 3
• STAAR-1 Clinical StudyCompletedNCT00369772Phase 4
• STAAR-3 Clinical StudyCompletedNCT00369733Phase 4
• STAAR-2 Clinical StudyCompletedNCT00368901Phase 4
• A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)CompletedNCT00189501
• Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)TerminatedNCT00156962Phase 3
• EPO Deep Tank in Dialysis SubjectsCompletedNCT00156949Phase 3
• Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving HemodialysisCompletedNCT00146224Phase 3
• START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary HyperparathyroidismCompletedNCT00132431Phase 4
• An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)CompletedNCT00124098Phase 3
• Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney DiseaseCompletedNCT00121602Phase 3
• Treatment for Subjects With Chronic Kidney Disease Receiving HaemodialysisCompletedNCT00116701Phase 3
• Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving DialysisCompletedNCT00112008Phase 3
• Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving HemodialysisCompletedNCT00111995Phase 4
• Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving DialysisCompletedNCT00111098Phase 3
• Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving DialysisCompletedNCT00096915Phase 3
• Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving DialysisCompletedNCT00094484Phase 3
• Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney DiseaseCompletedNCT00093977Phase 3